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We show that Met overexpression, as independently assessed by two immunohistochemical methods, is associated with significantly diminished disease-free survival (DFS) that is independent of HER2 overexpression.
Body-

Key Research Accomplishments
We collaborated with two groups (in Munich, Germany, and Chicago, U.S.A.) to determine the pattern and characteristics of these important tyrosine kinase receptor proteins in human primary breast cancer. The first was a small group of 40 cases with known clinical outcomes and follow up. This group established the parameters and profiles we would need to determine the same findings in our second collaborator's series. The second group also has known follow up but we are blinded to that information. The parameters and setting for the pilot study determine the methods for the main study.
In both cases, the receptor tyrosine kinases are well characterized as regards breast cancer.
Met and its ligand HGF/SF are potential candidates as targets for breast cancer therapy because of their in vitro ability to transform mammary epithelial cells and induce metastasis (2, 5 The ranking of cases in a variety of patterns has been completed. These include ranking by tumor expression, ranking by tumor to tumor ratio, ranking of Met-Her2neu ratios and amongst and between the two by the same categories. These are now being correlated with clinical outcomes by our collaborators and those results will be determined in early 2003 at the latest. A supplemental report with prognostic determinations will be submitted at that time. A draft of our submitted paper for the pilot study is provided (see appendix) and a set of representative images with digital files is also submitted for the larger study.
Reportable Outcomes
The determination of the protein expression of c-Met is a prognostic indicator of human primary breast cancer. The HER2 receptor tyrosine kinase is a well-characterized oncogene in breast cancer and is a target for an antibody-based tumor therapy approved for clinical use (11). No study has determined whether the Met is coordinately expressed with HER2 in breast cancer and, if so, whether their co-expression is clinically relevant. Given the important role of Met in tumor invasion and metastasis and the fact that HER2 is only positive in 20-30% of patients with breast cancer (12), we investigated whether Met is co-expressed in HER2 positive tumors.
Conclusions
We show that Met overexpression, as independently assessed by two immunohistochemical methods, is associated with significantly diminished disease-free survival (DFS) that is independent of HER2 overexpression. Table 1 ; established prognostic factors were dichotomized as described elsewhere (13). At time of primary therapy, no patient had any clinical or radiologic evidence of distant metastases. Follow-up data was obtained in regular intervals (13). Median follow-up in patients still living at time of analysis was 70 months (range: 12-122 months); 21 patients (53 %) experienced disease recurrence, the majority (n=18) at distant sites. In all patients, uPA and PAI-1 antigens have been measured by ELISA (uPA: Imubind # 894. PAI-1: Imubind #821; both from American Diagnostica, Greenwich, CT) (14) in a. prospective fashion since 1987 (13-14). Previously determined and re-evaluated optimized cutoff values were used for uPA (3 ng/mg protein) and PAI-1 (14 ng/mg protein) (13,14). The combination of both factors (uPA/PAI-1) was considered low if both factors were low and high if either or both were high (13,14).
MATERIAL AND METHODS
Conventional Immunohistochemical staining:
Expression of Met, HGF/SF, and HER2 in breast carcinoma tissue and lymph node metastases was determined by immunohistochemistry (IHC) using the following primary antibodies: Met (pAB C28), HGF/SF (pAB; both from Santa Cruz Biotechnology, CA, USA) and HER2 (pAB A0485, Dako, Denmark). A peroxidase-based visualization system was used together with the respective secondary antibodies. As positive controls, an NIH 3T3 cell line stably transfected with Met and HGF/SF (1,16) as well as HER2-overexpressing breast cancer tissue were used. Negative controls were performed by omission of the respective primary antibody. Immunohistochemical reactivity was scored independently by two staff pathologists (D.P. and T.R.) according to the immunoreactive score (IRS) first described by Remmele and Stegner (17) . For cytoplasmic Met (Met cyt ) and HGF/SF staining, the percentage of stained tumor cells was grouped into four categories: < 10, < 40, < 70, > 70 %. A scale from 0 (no staining) to 3 (intense staining) was assigned to staining intensity. The immunoreactive score from 0 to 12 (17) was assigned by multiplying positivity category times staining intensity. For Met membrane staining (Met mem ), a score from 0 (no membrane staining) to 2 (strong membrane staining) was applied. Optimized cutoffs determined by log-rank statistics were used for Met cyt (score 6), Met mem (score 1), and HGF/SF (score 3) to discriminate between high and low immunostaining in the primary tumor tissue. In the lymph node metastases, the respective cutoffs were score 8 for Met cyt , score 1 for Met mem , and score 6 for HGF/SF. Met cyt and Met mem were combined in order to enable assessment of total Met expression; High expression of both Met cyt and Met mem was considered Met overexpression.
HER2 immunostaining was performed and scored (0 to 3+) as done for clinical routine. A score of 3+ was considered HER2 overexpression. Distributions for Met, HGF/SF, and HER2 in primary tumors and axillary lymph node metastases are summarized in Table 2 .
Statistical Analysis: Correlations between continuous variables were analyzed using the Spearman rank test. Associations between continuous and/or categorical variables were analyzed using the Mann-Whitney U-test, the % 2 test, or the McNemar test as appropriate. Continuous variables were coded as binary variables by employing log-rank statistics to determine optimal cutoffs discriminating low and high-risk patients using the statistical programming environment S-Plus (MathSoft 1998) (13). For univariate analysis of diseasefree (DFS) survival, Kaplan-Meier curves were plotted and then compared using log-rank statistics. Multivariate analyses were performed in a stepwise forward fashion by applying the Cox proportional hazards model using the SPSS software package (SPSS Inc., Chicago, IL). All tests were performed at a significance level of a = 0.05.
Confocal microscopy / Immunofluorescence (IF) analysis:
Met and HER2 expression in primary tumors was assessed using an IF analysis staining protocol and a computerized evaluation algorithm as described earlier (4, 15) . Breast samples were stained using rabbit polyclonal antibody (pABC28) of Met (Santa Cruz). The indirect staining for Met was done with a rhodamine-labeled secondary antibody against rabbit immunoglobulin. The HER2 (c-neu) antigen was identified using a monoclonal antibody (Oncogene Science, MA). The indirect staining for HER2 was done using a FITC labeled secondary antibody against mouse immunoglobulin. The staining was imaged using a Zeiss 410 confocal microscope and the 8-bit digital images were stored to disk. The individual FITC or Rh images were evaluated using the Media Cybernetics image analysis program, Image Pro (Washington). The images were ranked according to their average intensity using pixels of intensity from 40-255 gray scales from the individual images. The images were ranked by their average intensity and cut-off values were established based upon intensity. We used "secondary only" stained controls as well as positive control cells from a cell line stably transformed with human Met that was prepared into a paraffin block.
The staining was ranked according to tumor intensity, ratio of tumor staining to adjacent, parallel uninvolved normal for those cases with both normal and tumor in the same section as well as against the control samples. The images were evaluated "qualitatively" as well as by image analysis. Those cases above the cut off were scored as positive. The review was independently done by three expert observers as well as by consensus review after individual ranking.
Statistical Analysis: For statistical analysis, the computer-calculated expression data were grouped as follows: for Met and for HER2, stronger expression in tumor than in surrounding normal tissue was considered overexpression (4, 15) . Lack of normal tissue in some sections did not allow determination of an IF score.
RESULTS
Conventional IHC and confocal IF render concordant results:
Both conventional IHC and confocal IF methods were used to analyze breast cancer patient specimens (Figure 1) . By IHE, two distinct staining patterns were observed for Met: cytoplasmic and membrane staining (Figure 1) . Membrane staining was observed only in tumor cells. Cytoplasmic staining in tumor cells was substantially stronger than in surrounding normal tissue with considerable variations between different tumors, independent of classical morphological criteria such as typing or differentiation. In normal tissue, only weak cytoplasmic staining (score 0-6) was seen, with higher expression observed in non-neoplastic alterations such as apocrine metaplasia, adenosis, and epithelial hyperplasia. In lymphatic tissue, no specific cellular Met staining was found and, with IHC, cytoplasmic staining was seen specific in tumor cells.
Determination of Met overexpression both by conventional IHC and confocal IF rendered concordant results (Figure 1) . Strikingly, all tumors with high Met expression by IHC were classified as having stronger Met expression than the adjacent equivalent normal breast epithelial tissue by confocal IF (T>N; r=0.41; p=0.01; see Table 3 ).
Differential expression of Met, HGF, and HER2 in primary tumor and corresponding lymph node metastasis by conventional IHC: A significant correlation between expression levels in primary breast carcinoma tissue and nodal metastasis was only found for Met cyt (r=0.39; p=0.017) and HER2 (r=0.59; p<0.001). HER2 overexpression in the primary tumor coincided with overexpression in the lymph node in 8/9 cases; an additional six cases overexpressed HER2 in the lymph node even though the primary tumor did not.
For Met mem and HGF/SF, expression patterns differed significantly between primary tumor and lymph node: for Met mem , six of the eight cases with overexpression in primary tumor also overexpressed Met mem in the lymph node; in addition, 10/26 cases with low expression in the primary tumor showed overexpression in the lymph node (p=0.039). For HGF/SF, 17/24 cases with overexpression in the primary tumor did not overexpress the ligand in the lymph node; in 12/14 cases with low HGF/SF expression in the primary tumor, low expression was also seen in the lymph node (p=0.001). With regard to Met and its ligand, HGF/SF, all Met overexpressing tumors (n=6) also overexpressed HGF/SF; both markers were low in 14 tumors and in the remaining 18 cases, HGF/SF overexpression was observed with low Met expression (p<0.001).
IHC Correlations and
Survival analysis
Patients with high Met mem by IHC had a median disease-free survival time of 14 months, in contrast to 56 months for the patients with low Met mem expression (univariate Kaplan-Meier analysis). However, while this difference fails significance (p=0.085) when total Met is used. The survival disadvantage associated with Met overexpression was significant (p=0.021): a median disease-free survival time of 8 months was seen in this high-risk group in contrast to 53 months in the remaining patients (Figure 2 
DISCUSSION
The receptor tyrosine kinase Met and its ligand HGF/SF are potential candidates as targets for breast cancer therapy because of their in vitro ability to transform mammary epithelial cells and induce metastasis (2, 5 ). An antibody (Herceptin®) against the HER2 receptor tyrosine kinase has shown clinical utility by improving survival in patients with HER2 positive breast cancer. Yet, only 20-30% of all breast cancer patients show HER2 overexpression and are thus eligible for Herceptin® therapy (12); this leaves the majority of patients without the option to be treated by this approach. Therefore, it is highly desirable to identify and characterize other biological targets in the group of patients which are not appropriate for therapy with Herceptin®. In a pilot study, we assessed expression and clinical impact of Met and its ligand HGF/SF in primary breast cancer tissue and corresponding lymph node metastasis and compared it to that of HER2. Our resultsobtained by two independent immunostaining techniques-substantiate the clinical relevance of Met (Table 3) .
We observed two distinct staining patterns for Met, cytoplasmic and membrane staining. Even though membrane staining seemed to be associated more strongly with tumor aggressiveness, the clinically most informative results were obtained by focusing on total Met expression (cytoplasmic + membrane staining) using either IF or conventional IHC staining (Figure 2 ) as previously shown in confocal IF (4) . Met overexpression was found both in the primary tumor tissue and in the corresponding lymph node metastasis suggesting an association with tumor progression and metastatic potential. Additional high-risk patients were identified according to Met overexpression in the lymph node metastasis. High expression of the ligand HGF/SF was associated with a better outcome, if it coincided with low Met expression. Although there may be other explanations, perhaps HGF/SF induces cell differentiation and Met downregulation (5) . In lymph node metastasis, HGF/SF expression was predominantly lower than in the primary tumor, possibly due to ligand utilization and receptor down modulation. Overexpression of both HGF/SF and Met in the primary tumor was associated with poor clinical outcome. This is concordant with in vitro and in vivo data showing that co-expression of the receptor and its ligand leads to increased tumor aggressiveness in a variety of solid tumors. Our data support the hypothesis that Met-HGF/SF signaling, and particularly the expression level of Met, is critical for the balance between cell differentiation and tumorigenicity (5).
The patients evaluated here with more than three involved axillary lymph nodes are highrisk breast cancer patients in whom assessment of the prognostic impact of tumor biological markers may be hampered by effects of adjuvant systemic therapy (18). Nevertheless, even within this group of patients at rather high risk of recurrence, high Met expression in primary tumor was associated with poor prognosis and all relapses in patients with tumors overexpressing Met occurred within the first 14 months after primary therapy, suggesting poor response to adjuvant systemic treatment. Clinical risk-group assessment obtained by Met was different than currently available tumor biological markers: it differed from that found with uPA/PAI-1 (data not shown), which are the only novel tumor markers that have reached the highest level of evidence (LOE I) for clinical utility (14) and which recognize a different group of patients at risk than HER2 (19, 20) . Risk group assessment by Met also differed from that of HER2 indicating that Met high-risk patients are not those who are already candidates for Herceptin™ therapy. It is important to note that these clinically relevant findings were independently determined using confocal IF and conventional IHC and scoring algorithms for Met and HER2 expression.
In conclusion, Met overexpression in primary node-positive breast carcinomas appears to correlate with tumor aggressiveness and failure of adjuvant systemic therapy. The differential expression of Met between primary tumor and lymph node metastasis and the correlation with high-risk patients identify Met as a novel target for tumor therapy, whether or not HER2 positive.
